Titre :

Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP.

Auteur(s) :

Onida, F. [Auteur]
Sbianchi, G. [Auteur]
Radujkovic, A. [Auteur]
Sockel, K. [Auteur]
Kröger, N. [Auteur]
Sierra, J. [Auteur]
Socié, Gerard [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Cornelissen, J. [Auteur]
Poiré, X. [Auteur]
Raida, L. [Auteur]
Bourhis, Jean Henri [Auteur]
Institut Gustave Roussy [IGR]
Finke, J. [Auteur]
Passweg, J. [Auteur]
Salmenniemi, U. [Auteur]
Schouten, H. C. [Auteur]
Beguin, Y. [Auteur]
Martin, S. [Auteur]
Deconinck, Eric [Auteur]
Hôpital JeanMinjoz
Ganser, A. [Auteur]
Zver, S. [Auteur]
Rohini, R. [Auteur]
Koster, L. [Auteur]
Hayden, P. [Auteur]
Iacobelli, S. [Auteur]
Robin, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Titre de la revue :

Bone Marrow Transplant

Nom court de la revue :

Bone Marrow Transplant

Numéro :

57

Pagination :

896–902

Date de publication :

2022-04-01

ISSN :

1476-5365

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: ...
Lire la suite >Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: WBC ≤ 10 × 109/l, circulating immature myeloid cells (IMC) = 0, no splenomegaly; (2) MD/MP (overlap)–CMML: WBC 10–20 × 109/l or WBC ≤ 10 × 109/l but IMC > 0 and/or splenomegaly; (3) Myeloproliferative (MP)-CMML: WBC > 20 × 109/l. By analysing EBMT Registry patients who underwent allo-HCT for CMML between 1997 and 2016, we aimed to determine the impact of this classification on transplantation outcome and to make a comparison with the conventional WHO classification (CMML-0/CMML-1/CMML-2). Patient grouping was based on the data registered at time of transplantation, with IMC replaced by peripheral blasts. Among 151 patients included in the analysis, 38% were classified as MD-CMML, 42% as MD/MP-CMML and 20% as MP-CMML. With a median survival of 17 months in the whole series, MD-CMML patients were distinguished as a low-risk group with higher CR rate at transplant and a longer post-transplant 2-year progression-free survival in comparison to others (44.5% vs 33.5%, respectively), whereas the WHO classification was superior in identifying high-risk patients (CMML-2) with inferior survival outcomes.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T01:53:05Z
2024-03-15T09:38:24Z